Jan 24 (Reuters) - X4 Pharmaceuticals Inc XFOR.O:
X4 PHARMACEUTICALS ANNOUNCES EMA VALIDATION OF MARKETING AUTHORIZATION APPLICATION $(MAA)$ FOR MAVORIXAFOR FOR THE TREATMENT OF WHIM SYNDROME
X4 PHARMACEUTICALS INC - DECISION ON MAVORIXAFOR MAA EXPECTED IN 1H 2026
X4 PHARMACEUTICALS INC: DECISION ON MAA EXPECTED IN 1H 2026
Source text: ID:nGNXbQj78L
Further company coverage: XFOR.O
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.